nafagrel has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagamatsu, T; Nagao, T; Suzuki, Y | 2 |
2 other study(ies) available for nafagrel and Bright Disease
| Article | Year |
|---|---|
Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
Topics: Animals; Antimetabolites; Azathioprine; Creatinine; Enzyme Inhibitors; gamma-Globulins; Glomerulonephritis; Imidazoles; Immunoenzyme Techniques; Male; Methacrylates; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Thromboxane-A Synthase | 1995 |
Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Antibodies; Azathioprine; Creatinine; Dinoprostone; Drug Interactions; Enzyme Inhibitors; Glomerulonephritis; Imidazoles; Immunoglobulin G; Immunosuppressive Agents; Kidney Glomerulus; Male; Methacrylates; Proteinuria; Rabbits; Rats; Rats, Sprague-Dawley; Renal Circulation; Tetrahydronaphthalenes; Thromboxane B2; Thromboxane-A Synthase | 1996 |